MyDrHank Reviews: The $137 Is a Twelve-Month Rate

The one-sentence version

MyDrHank sells NAD+ two ways most of this board does not — a daily nasal spray or a weekly subcutaneous injection — with the clinician review stated as free, no bloodwork required to start, and ongoing messaging with a care team inside the service. Then it does the one thing this board penalises hardest: the price it advertises, "Starting at $137/month," is the twelve-month plan's per-month rate on the cheaper of the two routes, and nothing on the page says so. Month to month, the same product is $199 for the nasal spray and $225 for the injection. It grades B, 10 points out of 14, and it loses all four of them in the same place. The grade is computed from published terms alone and cannot see who pays us — MyDrHank is a paid partner here.

What it is, and who it's for

The operator is Dr. Hank, LLC, trading as MyDrHank at mydrhank.com, and the site carries a LegitScript certification seal. It is a general telehealth platform, not a longevity clinic, and its own navigation says so: six lines sold from one account — Weight Loss, Longevity, Peptides & NAD+, Sexual Health, Hair Growth and Strength.

That matters for expectation-setting more than for grading. The longevity line itself is real and, verified on 7 August 2026, deeper than several specialists here: NAD+ Nasal Spray, NAD+ Injection, Glutathione Nasal Spray, Glutathione Injection and Sermorelin. Five of the fifteen products on the catalogue are the NAD+ and peptide routes this board is built to rank, which is the whole of the four points it takes on the longevity-line factor. But NAD+ sits on the same account as erectile-dysfunction tablets, finasteride and compounded tirzepatide, and if you want a practice whose entire business is the thing you are buying, System Labs and Telos Rx are the shape you are looking for.

Onboarding is deliberately frictionless: "A 3-minute medical questionnaire — no office visits, no insurance, no bloodwork required to start," then "A U.S. board-certified clinician reviews your intake within 24 hours and builds a protocol tailored to your goals." If you wanted baseline biomarkers before starting, nothing here measures anything — see longevity biomarker panels.

What it actually costs, and what "$137" is doing

All figures below were read on MyDrHank's own pages and published page data on 7 August 2026.

What the site shows you. The NAD+ lander leads with "Starting at $137" and /month, immediately under it "Final pricing depends on the protocol and dose prescribed," and at the foot of the offer "Free consultation · No insurance required · Cancel anytime. Prescription only following evaluation by a U.S.-licensed clinician. Available in select states." The product pages show the same figure in the same shape: "From $137 /mo." The sermorelin lander leads with $137 as well.

What the plans actually are. MyDrHank's own product catalogue prices each item on a four-tier ladder — Monthly, Quarterly, 6 Month and Yearly:

NAD+ Nasal Spray — Monthly $199; Quarterly $507 ($169/mo); 6 Month $913 ($152/mo); Yearly $1,644 ($137/mo).

NAD+ Injection — Monthly $225; Quarterly $574 ($191/mo); 6 Month $1,033 ($172/mo); Yearly $1,859 ($155/mo).

Sermorelin — Monthly $199; Quarterly $507 ($169/mo); 6 Month $913 ($152/mo); Yearly $1,644 ($137/mo).

So $137 is the twelve-month prepay rate on the nasal spray. It is not a monthly price, it is not the injection's price, and it is not a figure anyone is charged monthly. A buyer who wants to try NAD+ for a month and stop pays $199 or $225, which is 45% to 64% above the number that brought them to the page.

And here is the part that decides the price factor. Every price surface on mydrhank.com takes that four-tier ladder, reduces it to the lowest per-month value in it, and prints that alone under the word "From." The monthly, quarterly and six-month rates exist in the site's own product data and are rendered on no page we could find. So this is not a provider publishing a ladder and leading with the friendliest rung, the way System Labs prints its standing rate beside its teaser. It is a provider whose month-to-month price is not published at all, and whose published price is a twelve-month commitment with the term withheld.

Our rubric asks for a single all-in figure, visible before you commit, that a buyer with no commitment actually pays. There is no such figure here, so price transparency scores zero. Enhance MD advertises a $169 rate that requires a twelve-month prepay too — and keeps its four points, because the real month-to-month figure of $199 is published on the same page. That is the entire difference between the two rows.

One more qualifier on top. "Final pricing depends on the protocol and dose prescribed" sits directly beneath the headline, so even the $137 is a floor rather than a quotation.

The dose promise does not transfer. MyDrHank's weight-loss funnel makes a clean, checkable commitment in its own FAQ: "Plans start at $171/mo with no contract. This covers your physician review, personalized treatment plan, prescription medication, and free shipping directly to your door. The price stays the same at every dose — no surprise price increases." No equivalent promise appears anywhere on the NAD+ or sermorelin line. The longevity pages say the opposite — that final pricing depends on the dose prescribed. If you found MyDrHank through its GLP-1 marketing and assumed the dose-flat pricing carried across, it does not, and you should ask before you titrate. For what this category costs generally, see longevity clinic cost.

Clinical oversight and the pharmacy

Oversight: two points, earned. The NAD+ lander states "Free consultation" on its face and a banner across the top reads "Limited time — Free physician consultation with your first order." That is MyDrHank's own statement that the clinician review sits inside the price rather than being billed on top, which is the same standard that credited Strut Health for its free online MD visit. Note the framing honestly: it is described as a limited-time promotion tied to a first order, not a standing term, so confirm it is still on offer when you start.

Support: two points, earned. MyDrHank's own longevity page publishes "Ongoing clinical support — Check-ins, dose adjustments, and unlimited messaging with your care team" as part of the service. Stated support inside the price is what this factor asks for, and most of this board does not state it at all.

Pharmacy: two points, and they come with an asterisk. MyDrHank publishes a compounding standard on a surface it controls — its weight-loss lander footnotes read "Compounded semaglutide and tirzepatide are prepared by FDA-registered outsourcing or 503A pharmacies" — and our rule turns on where a claim is published, not on how prominently. So it scores the top rung. What you should know is that the claim is scoped to the weight-loss line. The disclosure attached to the products this review is actually about reads: "NAD+ dispensed through MyDrHank is a compounded medication prepared by a state-licensed U.S. compounding pharmacy. Compounded drugs are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality." That is a licence, not a section, and no dispensing facility is named on either line.

We could have written a sub-rule requiring the 503A claim to cover the graded product and scored this row zero. We did not, for the reason recorded against Shed when the same temptation came up there: inventing a rule after seeing which row it demotes is exactly the tuning a published rubric exists to prevent. The scoping is disclosed to you here instead, which is where it is useful. FDA's own position on what an unnamed compounder leaves open is blunt: compounded drugs are not FDA-approved, and the agency does not verify their safety, effectiveness or quality before they are marketed¹.

Where it will treat you. The consumer pages say only "Available in select states" and publish no list. The affiliate terms behind the program exclude Kansas, Louisiana, Mississippi, New Mexico, North Dakota and West Virginia — so a reader in one of those six should confirm before starting rather than after paying.

The evidence behind what it sells

MyDrHank markets NAD+ as "Steady, all-day cellular energy," "Sharper focus & mental clarity," "Better sleep & faster recovery" and "Supports healthy aging at the cellular level." Those are the category's standard claims, and the trial record does not carry them.

The 2026 PRISMA-guided systematic review of NAD+ for anti-aging and wellness screened 113 studies including 33 human intervention trials. Oral precursors reliably engage the target — blood NAD+ rises² — but effects on functional, metabolic and vascular outcomes were "heterogeneous and often null or endpoint-specific," and clinical effectiveness for anti-aging or wellness "remains inconclusive"³. The same review is blunter about the routes MyDrHank actually sells: no eligible outcomes trial has evaluated intravenous or intramuscular NAD+ for these indications at all³, and nasal delivery of NAD+ has less human outcome evidence still. A 2025 meta-analysis in adults averaging over 60 found NAD+ precursors did not improve muscle index, grip strength, gait speed or chair-stand time⁴; the strongest randomised trial in the field moved six-minute walk distance by roughly 17.6 metres in peripheral artery disease, a disease endpoint rather than an aging one⁵.

None of that is a mark against MyDrHank specifically — it is the state of the category, and this board grades providers rather than the medicine. But a buyer signing a twelve-month plan to reach $137 is committing about $1,644 to an intervention whose advertised outcomes have not been demonstrated in humans. Read NAD+ for longevity, do NAD+ peptides actually work and what's proven versus hyped before you decide the term is worth it.

Where it's weak, and who should skip it

Skip it if you intend to buy a month and stop, because that is precisely the purchase MyDrHank does not price: budget $199 for the nasal spray or $225 for the injection, not $137. Skip it if you need to know what the dose you end up on will cost, because the longevity line explicitly reserves that — and unlike the weight-loss line, it makes no promise that the price holds across doses. Skip it if you want to know which pharmacy fills your vial, since none is named on any line. And check the six excluded states before you start.

Buy it if the delivery routes are what you actually want. A daily nasal spray or a weekly injection, chosen by the prescriber rather than by whatever the shop happens to stock, with the visit free, no bloodwork gate, and unlimited messaging with a care team, is a genuinely reasonable starting position — provided you go in reading $199 rather than $137.

The verdict, against the rubric

Our rubric scores five things out of fourteen: price transparency (4), a genuine longevity line (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). MyDrHank takes the full four for its longevity line — NAD+ by two routes, glutathione by two more, plus sermorelin — two for clinical oversight, because the consultation is stated as free, two for human support, because ongoing check-ins and unlimited messaging are published as part of the service, and two for pharmacy, because a 503A claim appears on a surface it controls. It takes zero for price transparency, because no month-to-month figure is published anywhere and the number it does publish is a twelve-month rate with the term withheld. Ten out of fourteen: a B.

The fix is one line of HTML. MyDrHank already holds the monthly rate in its own product data; printing $199 beside $137 and labelling which is which would move this row to fourteen without changing a single term of the offer. Until it does, the headline is the cheapest thing about it. The full graded field is at our provider rankings, the scoring is set out in how we grade, and two neighbours with the same headline problem read differently: our Enhance MD review, which publishes the month-to-month price beside the prepay one, and our System Labs review, which publishes the standing rate beside the teaser.